Why the study?
Disproportionate concern over metabolic side effects has impacted the use of diuretics despite their proven benefits, while guidelines are increasingly differentiating between thiazide and thiazide-like diuretics.
Key points are not available for this paper at this time.
Design
Review
Answers are grounded in this paper and cite their sources.
Endorses thiazide-like diuretic preference in hypertension; leaves open need for prospective comparative trials.
: Diuretics are listed in hypertension guidelines as one of three equally weighted first-line treatment options. In order to differentiate between antihypertensives, a lot of discussion has been directed at side effect profiles and as a result, has created a perhaps disproportionate fear of the metabolic effects that can be associated with diuretics. Data, however, show that the risk of a clinically meaningful change in laboratory parameters is very low, whereas the benefits of volume control and natriuresis are high and the reductions in morbidity and mortality are clinically significant. Moreover, as clinically significant differences in safety and efficacy profiles exist among diuretics, several international guidelines have started making a distinction between thiazides (hydrochlorothiazide) and thiazide-like (chlorthalidone, indapamide) diuretics; and some of them now recommend longer acting thiazide-like diuretics. In time, pending more data, chlorthalidone and indapamide may need to be subdivided further into separate classifications.
No takes yet. Share an insight, caveat, or question.
Burnier et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: